Ellipses` RET Inhibitor EP0031/A400 Clears For Phase 2
01 May 2024 //
PR NEWSWIRE
Ellipses Pharma Announces Intent to Accelerate Clinical Programme
05 Jun 2023 //
BUSINESSWIRE
Ellipses Pharma: Expansion of Scientific Affairs Group
30 Mar 2023 //
BUSINESSWIRE
Ellipses Pharma: EP0042 Receives Orphan Drug Designation from FDA
14 Mar 2023 //
BUSINESSWIRE
Ellipses Pharma Announces FDA Approval of IND Application for EP0042
01 Feb 2023 //
BUSINESSWIRE
Ellipses Announces First Patient Dosed with EP0031
14 Dec 2022 //
BUSINESSWIRE